US 11318164
Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy
granted A61KA61K2239/57A61K38/2013
Quick answer
US patent 11318164 (Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy) held by Nektar Therapeutics expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Nektar Therapeutics
- Grant date
- Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K2239/57, A61K38/2013, A61K40/11, A61K40/4273